New evidence questions the simple link between prion proteins and vCJD
Research news from the Journal of PathologyWhile newly published research confirms that under laboratory circumstances prion-protein can be absorbed across the gut, it also shows that this is unlikely to occur in real life. In addition, the results show that the places in the gut that do take up these disease-associated proteins are different from the locations where infectivity is known to be amplified. The findings will be published in the Journal of Pathology.
Since the outbreak of BSE in cattle and vCJD in humans, scientists have struggled to make sense of how an abnormal variation of a normal protein can trigger an infectious disease. Some are questioning whether this simple relationship exists at all. This paper adds new evidence that can inform the debate.
Firstly, it is known that individual people and animals have different levels of genetic susceptibility to this group of diseases, but no one knows how this resistance is achieved. One option is that resistant people do not absorb the disease-associated prion protein (PrP) from their guts.
To test this, the researchers worked with 50 sheep, with different degrees of genetic resistance to scrapie – the sheep form of the disease. When they injected material containing abnormal prion protein (PrP) into the sheep's gut, it was equally absorbed by all sheep.
"This clearly shows that resistance is not achieved by blocking uptake of abnormal proteins from the gut – it must be achieved by some other mechanism," says lead author Dr Martin Jeffrey.
Secondly, they looked in more detail at the route of absorption in the gut. Using surgically modified sheep, they loaded a small area of the gut with a fluid mixture containing 0.5 grams of scrapie infected brain containing a large amount of the disease specific variant of the PrP protein and watched how it was taken up. They saw the abnormal PrP was rapidly taken up by finger-like projections called villi and passed in to the lymph. It was not, however, taken up by structures called Peyer's nodules, that are believed to be the places where animals amplify the infective agent.
"The fact the PrP isn't taken up by the Peyer's nodules questions whether PrP is really infectious, or whether PrP is really just a secondary marker of the presence of the scrapie agent," says Jeffrey.
His belief in this need to reappraise the fundamental understanding of prion diseases is enhanced by one more observation published in this same paper. The team pre-digested a mixture containing disease specific PrP with standard stomach contents, and then injected the resulting mixture into the gut. No PrP transferred into the villi. When they used a highly sensitive version of Western Blot analysis to examine the contents of this pre-digested mixture, they found only the faintest suggestion that some of the PrP had survived. This was despite the fact that the original mixture had a contained a high level of PrP.
"Think about it – a sheep grazing in a field is not naturally exposed to highly infected brain and could only pick up a tiny amount of PrP from other tissues. This will then be exposed to 48 hours or more digestion before it arrives in the gut, and our experiments show that after this, the chance of there being more than an unmeasurably small amount of PrP left to absorb is very small," says Jeffrey.
"As sheep can become infected, the theoretical probability of this being due to an invisible sub-fraction of digestion resistant PrP molecules is unlikely. The possibility of there being infectious molecules other than PrP must therefore be seriously considered," says Jeffrey.
"A lot of people are completely wedded to the prion hypothesis of diseases like vCJD, but the more you deal with whole animals as opposed to relying purely on in vitro studies, the more cautious you are about saying that prion proteins alone cause the disease," says Martin Jeffrey.
In a commentary published in the same edition of the journal Dr Nicole Sales of the Department of Infectology, at the Scripps Research Institute Jupiter, Florida, suggests that one possible explanation that keeps with the prion hypothesis is that infection occurs as PrPs are absorbed in the mouth, rather than in the gut.
Dr Jeffrey, however, is not convinced by this argument. "Were infection to be acquired from the mouth then the first tissues to accumulate infectivity would be lymph nodes in the throat or the tonsils. But we don't tend to see this in animals, and have no reason to believe it would be different in humans," comments Jeffrey.
Notes to editors
Jeffrey, M et. al: Transportation of prion protein across the intestinal mucosa of scrapie-susceptible and scrapie-resistant sheep: Journal of Pathology 2006: Vol. 209; Issue 1. DOI: 10.1002/path.1962
Sales, N: What can we learn from the oral intake of prions by sheep? Journal of Pathology 2006: Vol. 209; Issue 1. DOI: 10.1002/path.1977
To obtain a full copy of the article or for any further information, please contact Polly Young on 01243 770633 or email [email protected]. The articles will be available online from 30th March 2006 in the News section of the Journal of Pathology http://www.interscience.wiley.com/thejournalofpathology
About the Journal:
The Journal of Pathology is an official journal of the Pathological Society. The Journal publishes high quality, influential papers in the fields of pathology and clinico-pathological correlation as well as experimental pathology relevant to the understanding of human disease. The main interests of the Journal of Pathology lie in the pathophysiological and pathogenetic mechanisms of human disease and in the application of such knowledge to diagnosis and prognosis. The Journal of Pathology can be accessed online at: http://www.interscience.wiley.com/thejournalofpathology
John Wiley & Sons Ltd., with its headquarters in Chichester, England, is the largest subsidiary of John Wiley & Sons, Inc. Founded in 1807, John Wiley & Sons, Inc., provides must-have content and services to customers worldwide. Its core businesses include scientific, technical, and medical journals, encyclopaedias, books, and online products and services; professional and consumer books and subscription services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley has publishing, marketing, and distribution centres in the United States, Canada, Europe, Asia, and Australia. The company is listed on the New York Stock Exchange under the symbols JWa and JWb. Wiley's Internet site can be accessed at http://www.wiley.com/
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.